SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-06-17
👔
Hemab Therapeutics Holdings, Inc.
@COAG_InsiderForm 4 Filing: RA CAPITAL MANAGEMENT, L.P. Buys $1.7M of $COAG
INSIDER PURCHASE
⚡ MATERIALITY: 7/10
corporate issuer
Hemab Therapeutics Holdings, Inc.
Ticker: $COAG
Transaction Value
$1.7M
Price/Share: $24.97
transaction date
2026-06-16
Shares: 67,669
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, RA CAPITAL MANAGEMENT, L.P., holds the title of 10% Owner at Hemab Therapeutics Holdings, Inc..
On 2026-06-16, the insider transacted 67,669 shares.The shares were transacted at a weighted average price of $24.97 per share, resulting in a total market-relevant value of $1.7M.
Executive Summary Summary
RA CAPITAL MANAGEMENT, L.P. (10% Owner) bought $1.7M of $COAG
Post-Transaction Position: 6,444,637 shares
SEC Accession No: 0001231919-26-000665 (CIK: 1346824)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.